Mydlo J H, Usher S M, Camacho F, Freed S
Urology. 1986 Sep;28(3):173-5. doi: 10.1016/0090-4295(86)90036-1.
This is a review of 100 patients at our institution who were treated for superficial bladder cancer. In those patients with carcinoma in situ of the bladder who were treated with conventional therapy (resection and/or fulguration) and intravesical bacillus Calmette-Guerin (BCG) without intradermal BCG, and those patients who were treated with conventional therapy alone, we found a response rate of 60 per cent versus 40 per cent at the end of three months. In comparing those patients with superficial papillary cancer, we found a response of 39 per cent after conventional therapy and 63 per cent after conventional therapy and intravesical BCG. This suggests that intravesical BCG without intradermal BCG can be an important adjunct to the conventional therapy of bladder tumors.
这是对我院100例浅表性膀胱癌患者治疗情况的回顾。在那些接受传统治疗（切除和/或电灼）并膀胱内灌注卡介苗（BCG）但未进行皮内注射BCG的膀胱原位癌患者，以及那些仅接受传统治疗的患者中，我们发现在三个月末，前者的缓解率为60%，而后者为40%。在比较那些浅表乳头状癌患者时，我们发现传统治疗后的缓解率为39%，而传统治疗加膀胱内BCG后的缓解率为63%。这表明不进行皮内注射BCG的膀胱内BCG可成为膀胱肿瘤传统治疗的重要辅助手段。
